17 completed, 6 terminated, 3 recruiting, 3 unknown. 10 Phase 2, 9 Phase 3, 5 Not applicable, 5 Phase 4, 3 Phase 1.
Follow Meniere's Disease: new trials by email Literature Review of Meniere's Disease trials Research Report on Meniere's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPI-1005 for the Treatment of Meniere's Disease (Open Label) Ebselen - Meniere's Disease, Ménière's Disease | Phase 3 | Active not recruiting | Sound Pharmaceuticals, Incorporated | 200 | 2025-10-29 | 2026-07-13 |
| Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes a blood withdrawal will be obtained, blood withdrawal - Vertigo, Meniere's Disease | Recruiting | IRCCS San Raffaele | 250 | 2025-04-09 | 2026-04-08 | |
| Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation YPS-201b, betahistine - Meniere's Disease | Phase 1 / Phase 2 | Unknown | Seoul National University Hospital | 120 | 2023-09-18 | 2024-12-05 |
| Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets Meniere's Disease, Enlarged Vestibular Aqueduct Syndrome | Recruiting | National Institute on Deafness and Other Communication Disorders (NIDCD) | 210 | 2021-08-17 | 2026-06-29 | |
| CAVA: Dizziness Trial CAVA Device - Meniere's Disease, Benign Paroxysmal Positional Vertigo | Not applicable | Completed | Norfolk and Norwich University Hospitals NHS Foundation Trust | 29 | 2019-07-01 | 2026-08-10 |
| Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) - Autoimmune Inner Ear Disease, Meniere's Disease | Phase 2 | Recruiting | Northwell Health | 57 | 2019-01-03 | 2026-04-15 |
| SPI-1005 for the Treatment of Patients With Meniere's Disease 200mg SPI-1005 BID, 400mg SPI-1005 BID, Placebo - Meniere's Disease | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 149 | 2017-09-28 | 2023-09-18 |
| A 6-Month Extension Study of OTO-104 in Meniere's Disease OTO-104 - Meniere's Disease | Phase 3 | Terminated | Otonomy, Inc. | 142 | 2016-08-01 | 2023-01-20 |
| Open Label Study of OTO-104 in Subjects With Meniere's Disease OTO-104 - Meniere's Disease | Phase 2 | Terminated | Otonomy, Inc. | 34 | 2016-06-01 | 2017-09-15 |
| Study of OTO-104 in Subjects With Unilateral Meniere's Disease OTO-104, Placebo - Meniere's Disease | Phase 3 | Terminated | Otonomy, Inc. | 176 | 2016-03-21 | 2023-01-13 |
| Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease Gadolinium - Meniere's Disease | Phase 4 | Terminated | University Hospital, Grenoble | 23 | 2016-03-16 | 2020-11-18 |
| A 6-Month Extension Study of OTO-104 in Meniere's Disease OTO-104 - Meniere's Disease | Phase 3 | Terminated | Otonomy, Inc. | 189 | 2016-02-01 | 2022-12-14 |
| Study to Evaluate SPI-1005 in Adults With Meniere's Disease SPI-1005 - Meniere's Disease | Phase 1 / Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 40 | 2015-12-01 | 2026-06-29 |
| Study of OTO-104 in Subjects With Unilateral Meniere's Disease OTO-104, Placebo - Meniere's Disease | Phase 3 | Completed | Otonomy, Inc. | 166 | 2015-10-27 | 2023-01-12 |
| Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach Cochlear Implant - Unilateral Acoustic Neuroma, Meniere's Disease | Not applicable | Completed | University of North Carolina, Chapel Hill | 10 | 2014-11-01 | 2019-01-07 |
| A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom OTO-104, Placebo - Meniere's Disease | Phase 2 | Completed | Otonomy, Inc. | 128 | 2014-10-01 | 2017-08-18 |
| Study of Lamotrigine to Treat Ménière's Disease Lamotrigine, Placebo - Meniere's Disease, Ménière's Vertigo | Phase 2 | Completed | Dent Neuroscience Research Center | 15 | 2014-06-01 | 2022-06-22 |
| OTO-104 for the Treatment of Meniere's Disease OTO-104, Placebo - Meniere's Disease | Phase 2 | Completed | Otonomy, Inc. | 154 | 2013-11-01 | 2015-09-03 |
| Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets Meniace, Isobide - Meniere's Disease | Phase 4 | Completed | Alvogen Korea | 220 | 2013-02-01 | 2016-03-24 |
| Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent Magnevist (gadopentetate dimeglumine) - Meniere's Disease | Not applicable | Completed | University of California, San Diego | 6 | 2012-01-01 | 2016-02-12 |
Showing 20 of 31. Sign in to see all of them.
Meniere Disease (31) · Vertigo (11) · Hearing Loss (6) · Tinnitus (6) · Dizziness (3) · Benign Paroxysmal Positional Vertigo (1) · Diabetes Insipidus (1) · Diabetes Insipidus, Nephrogenic (1) · Endolymphatic Hydrops (1) · Hearing Loss, Sudden (1) · Neuroma, Acoustic (1) · Nystagmus, Pathologic (1) · Speech (1) · Vestibular Diseases (1) · Vestibular Neuronitis (1)
Ear Diseases (31) · Labyrinth Diseases (31) · Otorhinolaryngologic Diseases (31) · Endolymphatic Hydrops (30) · Nervous System Diseases (14) · Neurologic Manifestations (14) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (14) · Vestibular Diseases (11) · Sensation Disorders (9) · Hearing Disorders (7) · Cranial Nerve Diseases (2) · Retrocochlear Diseases (2) · Vestibulocochlear Nerve Diseases (2) · Behavior (1)
ebselen (4) · Betahistine (2) · Steroids (2) · Acyclovir (1) · BID protein, human (1) · Cochlear Implants (1) · Famciclovir (1) · Gadolinium (1) · Gadolinium DTPA (1) · Gentamicins (1) · Injection, Intratympanic (1) · Interleukin 1 Receptor Antagonist Protein (1) · Lamotrigine (1) · Methylprednisolone (1) · Pharmaceutical Preparations (1)
Otonomy, Inc. (8) · Sound Pharmaceuticals, Incorporated (4) · Osaka University (2) · Alvogen Korea (1) · Beijing Administration of Traditional Chinese Medicine Bureau (1) · Dent Neuroscience Research Center (1) · House Research Institute (1) · IRCCS San Raffaele (1) · Imperial College London (1) · Klinikum der Universitaet Muenchen, Grosshadern (1) · National Institute on Deafness and Other Communication Disorders (NIDCD) (1) · Norfolk and Norwich University Hospitals NHS Foundation Trust (1) · Northwell Health (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Seoul National University Hospital (1)
United States (14) · United Kingdom (3) · France (2) · Japan (2) · Australia (1) · Canada (1) · China (1) · Germany (1) · Iran (1) · Italy (1) · South Korea (1)
Kathie Bishop, PhD (5) · Carl LeBel, PhD (3) · Jonathan Kil, MD (2) · Tadashi Kitahara, M.D.,Ph.D. (2) · Adolfo M Bronstein, PhD, FRCP (1) · Andrea Vambutas, MD (1) · Eike Krause, MD (1) · Jennifer Derebery, MD (1) · Jianping Jia, MD (1) · John Phillips, Consultant (1) · Kevin Brown, MD, PhD (1) · Lixin Zhang, MD, PhD (1) · Michael Hoa, M.D. (1)
PMID 37185596, PMID 21199898, PMID 24979126, PMID 25133431, PMID 25814661, PMID 27362705, PMID 27865535, PMID 32483557, PMID 34510123, PMID 39973595, PMID 40596438